Republished: Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency
Case report highlights this potential side effect. It reasserts advice that patients should be vitamin D replete (>50 nmol/L) prior to administration. Also monitoring of calcium, ideally 8–14 days post-administration should be done with all patients at risk of hypocalcaemia.
Source:
Drug and Therapeutics Bulletin